A simple blood test can predict that if a patient develops Alzheimer's disease for 16 years before symptoms begin, a new study has been reported.
By measuring changes in protein levels in the blood that are known as the neurophilimet light chain (NFL), researchers believe that any rise in protein levels may be an early sign of this disease. .
Professor lead researcher Matthias Jaker, of cell biology of neurological disease in the German Center Center for Neurogenic Diseases, said that the NFL "is a marker in the blood that indicates nerve cell damage in the brain." "You have more neurophilia in the blood, as much as you have brain damage," he said.
There is still no effective treatment for Alzheimer's, but the juicer thinks that new blood tests are very important for clinical studies. They hope that by measuring how this test affects the level of the protein, people allow researchers to monitor the effectiveness of new therapies before they start experiencing symptoms.
Jack Alder, board director of the Harty Institute of Clinical Brain Research, Tubingan University, said, "Alzheimer's disease starts at least a decade, probably even before 20 years, before it has any symptoms."
Currently, no testing doctors can use to determine precisely whether someone will get Alzheimer's disease and many strangers are concerned about its causes. A widely recognized theory is that this disease is managed by the production and deposition of beta-amyloid plates between neurons in the brain.
In the United Kingdom, 850,000 people live from dementia, and according to the Alzheimer's Society in the UK, this condition is the most common type of Alzheimer's disease. US According to the Centers for Disease Control and Prevention, 5 million Americans have Alzheimer's disease.
Many changes in the brain, which are before the symptoms of the disease, before any symptoms start before the accumulation of the NFL in blood, Jaker said.
The Jucker team has measured the change rate in the NFL, which uses blood tests registered in the Dominion Inherited Alzheimer's network around the world – an international research effort mainly focusing on hereditary Alzheimer's Disease, which is rarely a disease which states that the National Institute on According to Aging, 1% in all cases of Alzheimer's.
The team has measured NFL protein levels in participants through blood samples, brain imaging and cognitive tests in the last seven years. The study is underway.
243 Group Group – Nephil levels were seen in the level of NFL compared to the control group, which resulted in patients with gene changes resulting in alzheimer's disease, which had 162 family members without change.
By measuring proteins, Jacques said, "many years before the symptoms of our symptoms, changes in the brain are measured with our blood tests." So far, 13 participants developed alzheimer's.
By cognitive testing and imaging of the brain, the NFL level is correlated with cognitive impairment and brain contraction, he said. Researchers then found a connection between 39 participants' NFL levels and brain loss and cognitive impairment after two years.
According to the study, changes in NFL levels show that how the brain damage develops is a precursor.
He also compared his team's work to the cancer sector.
"Generally, this is not something new," he explained as specific markers, for example, even though people have a problem with this disease, tell them to have cancer. This test is already commercially available; It detects NFL in the cerebrospinal fluid for the size of various neuromuscular conditions, and Juker believes that the new Alzheimer's drugs will include its team's developer in future clinical trials.
But Jukker warns that this test is not specific for Alzheimer's Diseases. Higher levels of neurophilia suggest damage to the brain, but for example, this may also happen due to brain injury in the accident.
The first blood test developed in the hope of early diagnosis of this disease is not.
Previous research has shown alternatives to finding Alzheimer's disease in its early stages. In a study of 2018, the presence and level of amyloid beetroot were examined in people's brains, in which people with healthy levels were monitored, some of which were healthy, some had mild cognitive impairments, and some people who had Alzheimer's disease.
In 2014, researchers were also able to predict the symptoms before Elizabeth's formulation, using a blood test, observing 10 specialized lipids in people's blood.
Sarah Marzie, postdoctoral researcher of the Queen Mary University of London, said that researchers "the most promising" NFL's inventive test results and forecasts of Cortex's things, "the two main symptoms of Alzheimer's disease." Shows the changes.
Marzi was not involved in the research, he told CNN in an email, "If this result can be copied to a larger group and is more commonly copied in unusual cases of Alzheimer's Disease, blood testing for the NFL will be really promising biomarker or diagnostic. . "
"However, so far the authors have shown only those small samples (39 individuals) who have altered the risk of Alzheimer's disease."
Dr. Charles Marshall, Queen Mary University's London clinical lecturer in Neurology, told CNN in an email, "This is exciting because it allows early treatment to start and therefore stops the development of dementia."